News

Sunstone Life Science Fund II portfolio company Orpahzyme, publishes an offering circular and the indicative price range in connection with its intended initial public offering (“IPO” or the “Offering”) and subsequent admission to trading and official listing of its shares on Nasdaq Copenhagen.

For a further description of the Offering, please refer to www.orphazyme.com.

Sunstone Life Science Fund III portfolio company  Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it has received orphan drug designation (ODD) from United States Food and Drug Administration for myelodysplastic syndromes (MDS).

Sunstone Life Science Fund II portfolio company Orpahzyme, announces its intention to launch an Initial Public Offering (“IPO” or “Offering”) of its shares and to apply for admission to trading and official listing on Nasdaq Copenhagen. The intended IPO is expected to consist of an issue of new shares to raise gross proceeds of approximately DKK 600 million to support the Company’s strategy by primarily funding on-going and planned clinical trials within four orphan diseases. The total offer size will be announced in connection with the publication of a prospectus by the Company.

For full text of the announcement, please refer to www.orphazyme.com

Starting immediately, Arcoma will be selling Arcoma branded systems integrated with Canon image software and detectors throughout Europe, the Middle East and Africa.

Until now, Canon distributors have bought the image software and the detectors directly from Canon Europe, having two points of sourcing for a complete system. This new agreement allows Arcoma to deliver the completely integrated system, ensuring functionality, quality and reducing installation time for its customers. The agreement will increase Arcoma sales by approx. 25 MSEK per year and will strengthen the Arcoma brand in Europe considerably.

“We are proud to be able to sell the complete Arcoma branded systems with the Canon detectors throughout EMEA. The strengthened alliance with Canon allows us to pre-stage systems prior to installation, thus reducing installation time for end-users and ensuring system functionality and quality. This is further an important part of Arcoma’s strategy to strengthen the Arcoma brand and increase its product offering”, says CEO Mikael Högberg.

Life Science Ventures Fund II portfolio Company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that preclinical data with its oral T-cell immunotherapy platform, including one preclinical development candidate, VXM10, are being presented at the upcoming “AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications” being held October 26-30, 2017 in Philadelphia, PA, USA. The poster will be presented during Poster Session B in session category “Tumor Immunology Targets” on Sunday October 29, 12:30 PM – 4:00 PM in Hall E.